Mosaic ImmunoEngineering (OTCMKTS:CPMV) Issues Quarterly Earnings Results

Mosaic ImmunoEngineering (OTCMKTS:CPMV) released its quarterly earnings data on Wednesday. The company reported ($0.02) earnings per share for the quarter, Zacks reports.

Mosaic ImmunoEngineering Stock Performance

CPMV stock remained flat at $0.60 during trading on Wednesday. 3 shares of the company were exchanged, compared to its average volume of 1,267. Mosaic ImmunoEngineering has a 12 month low of $0.25 and a 12 month high of $1.05. The business’s 50 day moving average price is $0.67 and its 200 day moving average price is $0.54. The stock has a market cap of $4.35 million, a P/E ratio of -6.00 and a beta of -1.04.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.